NCT07328178 Analysis of the Role of IgE Proteoforms in Health and Disease
| NCT ID | NCT07328178 |
| Status | Recruiting |
| Phase | — |
| Sponsor | KU Leuven |
| Condition | Anaphylaxis |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2029-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-01-01 with a primary completion date of 2029-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to evaluate the role of IgE proteoforms in healthy volunteers and in patients with type I allergy, patients with chronic spontaneous urticaria, patients with a recent history of anaphylaxis, patients with mastocytosis, patients with hereditary alpha tryptasemia, patients with X-linked agammaglobulinemia (XLA), and patients undergoing desensitization for venom or medication allergy.
Eligibility Criteria
Inclusion Criteria: * CSU and type I allergic diseases (including anaphylaxis and desensitization), atopic dermatitis, mastocytosis, XLA and HaT (informed consent, age: any available adult subject, gender: any available subject, clinical phenotype and specific information about the allergy (e.g. severity, medication, medical history, laboratory testing) * Healthy controls (informed consent, age matched to the allergic patients, gender matched to the allergic patients, patient-reported symptoms related to allergy to aeroallergens, food, drugs, hymenoptera venom, CSU) Exclusion Criteria: * Absence of informed consent * Age \< 18 years old
Contact & Investigator
Rik Schrijvers, MD, PhD
PRINCIPAL INVESTIGATOR
UZ/KU Leuven
Frequently Asked Questions
Who can join the NCT07328178 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Anaphylaxis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07328178 currently recruiting?
Yes, NCT07328178 is actively recruiting participants. Visit ClinicalTrials.gov or contact KU Leuven to inquire about joining.
Where is the NCT07328178 trial being conducted?
This trial is being conducted at Leuven, Belgium.
Who is sponsoring the NCT07328178 clinical trial?
NCT07328178 is sponsored by KU Leuven. The principal investigator is Rik Schrijvers, MD, PhD at UZ/KU Leuven. The trial plans to enroll 200 participants.